SEN34625/WYE-103914 is the more effective analogue of previously prepared compound SEN12333 (5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide) promising for Alzheimer’s disease and schizophrenia treatment with median effective concentration to α7 nAChR 12 μM [95]. Here, CHRNA7 is linked to early-onset autosomal dominant Alzheimer disease.